BRPI0911998A2 - métodos e kits para o tratamento de condições de desordem inflamatória intestinal - Google Patents

métodos e kits para o tratamento de condições de desordem inflamatória intestinal

Info

Publication number
BRPI0911998A2
BRPI0911998A2 BRPI0911998A BRPI0911998A BRPI0911998A2 BR PI0911998 A2 BRPI0911998 A2 BR PI0911998A2 BR PI0911998 A BRPI0911998 A BR PI0911998A BR PI0911998 A BRPI0911998 A BR PI0911998A BR PI0911998 A2 BRPI0911998 A2 BR PI0911998A2
Authority
BR
Brazil
Prior art keywords
kits
treatment
methods
inflammatory bowel
bowel disorder
Prior art date
Application number
BRPI0911998A
Other languages
English (en)
Inventor
Bruce Rudolf Yacyshyn
Simon Henry Magowan
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BRPI0911998A2 publication Critical patent/BRPI0911998A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0911998A 2008-05-01 2009-04-30 métodos e kits para o tratamento de condições de desordem inflamatória intestinal BRPI0911998A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4945008P 2008-05-01 2008-05-01
PCT/US2009/042196 WO2009134948A1 (en) 2008-05-01 2009-04-30 Methods and kits for the treatment of inflammatory bowel disorder conditions

Publications (1)

Publication Number Publication Date
BRPI0911998A2 true BRPI0911998A2 (pt) 2015-10-13

Family

ID=40793070

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911998A BRPI0911998A2 (pt) 2008-05-01 2009-04-30 métodos e kits para o tratamento de condições de desordem inflamatória intestinal

Country Status (9)

Country Link
US (1) US20090274662A1 (pt)
EP (1) EP2280713A1 (pt)
CN (1) CN102014926A (pt)
AU (1) AU2009243066A1 (pt)
BR (1) BRPI0911998A2 (pt)
CA (1) CA2721981A1 (pt)
MX (1) MX2010011995A (pt)
RU (1) RU2010143460A (pt)
WO (1) WO2009134948A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158384A1 (en) * 2008-06-27 2009-12-30 The Procter & Gamble Company Methods and kits for the treatment inhibition, and maintenance of gastrointestinal disorders
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
DK2481299T3 (en) * 2011-01-31 2017-02-06 Dr Fischer Gesundheitsprodukte Gmbh BIFIDOBACTERIUM BIFIDUM STREAMS FOR USE IN GASTROINTESTINAL DISEASES
WO2013036783A2 (en) 2011-09-09 2013-03-14 Cubist Pharmaceuticals, Inc. Methods for treating intrapulmonary infections
EP2797432A2 (en) 2011-12-27 2014-11-05 Abbott Laboratories Use of reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life
WO2013163582A1 (en) 2012-04-27 2013-10-31 Cedars-Sinai Medical Center Fungal mycobiome as probiotics, diagnostics and therapeutics
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
KR102329764B1 (ko) 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
AU2015259359A1 (en) 2014-05-12 2016-11-17 BiOWiSH Technologies, Inc. Compositions and methods for improving human health and nutrition
EP3164145A4 (en) 2014-07-01 2018-01-17 Probi Usa, Inc. Bi-layer dual release probiotic tablets
WO2016130830A1 (en) * 2015-02-11 2016-08-18 The Fix, Llc Compositions and methods for combination ingredient delivery
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) * 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
DK3503738T3 (da) * 2016-08-26 2021-06-07 Nutreco Ip Assets Bv Dyrefodertilskud og dyrefoder indeholdende det
CN107823204B (zh) * 2017-10-30 2020-05-05 江苏理工学院 一种吉米沙星的新用途
AT16167U1 (de) * 2017-11-08 2019-03-15 Alcus Med Gmbh Kombinationspräparat zur diätetischen behandlung von darmbeschwerden bei reizdarmsyndrom
WO2019232026A1 (en) 2018-05-29 2019-12-05 BiOWiSH Technologies, Inc. Compositions and methods for improving survivability of aquatic animals
ES2752798B2 (es) * 2018-10-05 2020-08-12 Consejo Superior Investigacion Cepa de Bifidobacterium longum sub. infantis y uso de la misma
US12053447B2 (en) * 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
WO2021110127A1 (en) * 2019-12-06 2021-06-10 Cheer Global Limited Method of treating inflammatory bowel disease
CN114965764B (zh) * 2022-05-18 2024-12-31 陕西安宁云生生物技术有限公司 便秘的诊断和治疗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6929M (pt) * 1967-11-29 1969-05-05
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
AUPM596894A0 (en) * 1994-05-30 1994-06-23 Hybrid Scientific Pty Ltd Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
CA2285923C (en) * 1997-04-01 2013-03-12 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
EP1313699B1 (en) * 2000-08-29 2010-03-10 Biocon Limited 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
EP1481681A1 (en) * 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof
RU2297835C1 (ru) * 2005-09-26 2007-04-27 Закрытое акционерное общество "Партнер" Препарат для лечения неинфекционных воспалительных болезней кишечника
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions

Also Published As

Publication number Publication date
RU2010143460A (ru) 2012-06-10
WO2009134948A1 (en) 2009-11-05
CA2721981A1 (en) 2009-11-05
EP2280713A1 (en) 2011-02-09
AU2009243066A1 (en) 2009-11-05
MX2010011995A (es) 2010-12-02
CN102014926A (zh) 2011-04-13
US20090274662A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
BRPI0917130A2 (pt) biomarcadores para tratamento anti-tnf de colite ulcerativa e transtornos relacionados
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0812767A2 (pt) Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
ZA201009030B (en) Methods of treating inflammatory colon disease
BRPI0924069A2 (pt) métodos de diagnosticar e tratar disfagia
BRPI0819076A2 (pt) aparelho para tratamento de água
GB2450974B (en) Treatment of inflammatory bowel disease with cannabinoids
PT2894165T (pt) Métodos e composições para o tratamento de distúrbios associados ao complemento
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
BRPI0920072A2 (pt) métodos para separação e caracterização de micro-organismos por agentes identificadores
BRPI0911735A2 (pt) aparelho e método para o tratamento de água de lastro
HUE040445T2 (hu) Antiszensz molekulák és eljárások betegségek kezelésére
BRPI0908276A2 (pt) Métodos de tratar dor inflamatória
BRPI0717482A2 (pt) Sistema para o tratamento de uma alimentação de hidrocarboneto
BRPI0918693A2 (pt) dispositivos para amostragem e métodos para concentração de microorganismos
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
BRPI0814330A2 (pt) métodos e kits cirúrgicos
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BR112012001100A2 (pt) aparelho e método para construções de estrutura e tijolo
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0919127A2 (pt) métodos para tratamento de água
PT2340042E (pt) Métodos e composições para o tratamento de cancro

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.